Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse eventsMarie Kostine, Thierry Schaeverbeke, Alice Tison et al.|European Journal of Cancer|2021Cited by 93
Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational studyAlexandra Ladouceur, Marie Kostine, Mathieu Larroquette et al.|RMD Open|2023Cited by 9